Premium
Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients
Author(s) -
Macesic Nenad,
Laplante Jennifer M.,
Aaron Justin G.,
DiMango Emily A.,
Miko Benjamin A.,
Pereira Marcus R.,
Reshef Ran,
St. George Kirsten
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13542
Subject(s) - oseltamivir , zanamivir , medicine , neuraminidase inhibitor , viral shedding , combination therapy , virology , drug resistance , covid-19 , virus , microbiology and biotechnology , disease , infectious disease (medical specialty) , biology
Few treatment options are available for oseltamivir‐resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients. We report two such cases treated with baloxavir after failure of oseltamivir and detection of oseltamivir resistance mutations. Baloxavir/zanamivir combination therapy was effective in one patient, but persistent viral shedding was noted with baloxavir monotherapy in the other patient.